Cargando…

Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals

INTRODUCTION: The lack of feasible therapies and comorbidities aggravate the COVID-19 case–fatality rate (CFR). However, reports examining CFR associations with diabetes, concomitant cardiovascular diseases, chronic kidney disease, and chronic liver disease (CLD) are limited. More studies assessing...

Descripción completa

Detalles Bibliográficos
Autores principales: Said, Kamaleldin B, Alsolami, Ahmed, Alreshidi, Fayez Saud, Fathuddin, Anas, Alshammari, Fawwaz, Alrashid, Fauwaz, Aljadani, Ahmed, Aboras, Rana, Alreshidi, Fatmah, Alghozwi, Mohammed H, Alshammari, Suliman F, Alharbi, Nawaf F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162097/
https://www.ncbi.nlm.nih.gov/pubmed/37153358
http://dx.doi.org/10.2147/JMDH.S403700
_version_ 1785037629688905728
author Said, Kamaleldin B
Alsolami, Ahmed
Alreshidi, Fayez Saud
Fathuddin, Anas
Alshammari, Fawwaz
Alrashid, Fauwaz
Aljadani, Ahmed
Aboras, Rana
Alreshidi, Fatmah
Alghozwi, Mohammed H
Alshammari, Suliman F
Alharbi, Nawaf F
author_facet Said, Kamaleldin B
Alsolami, Ahmed
Alreshidi, Fayez Saud
Fathuddin, Anas
Alshammari, Fawwaz
Alrashid, Fauwaz
Aljadani, Ahmed
Aboras, Rana
Alreshidi, Fatmah
Alghozwi, Mohammed H
Alshammari, Suliman F
Alharbi, Nawaf F
author_sort Said, Kamaleldin B
collection PubMed
description INTRODUCTION: The lack of feasible therapies and comorbidities aggravate the COVID-19 case–fatality rate (CFR). However, reports examining CFR associations with diabetes, concomitant cardiovascular diseases, chronic kidney disease, and chronic liver disease (CLD) are limited. More studies assessing hydroxychloroquine (Hcq) and antivirals are needed. PURPOSE: To examine associations of COVID-19 CFR in comorbid patient groups each with single comorbidities and after treatment with Hcq, favipiravir, and dexamethasone (Dex), either alone or in combination versus standard care. METHODS: Using statistical analysis, we descriptively determined these associations among 750 COVID-19 patient groups during the last quarter of 2021. RESULTS: A diabetes comorbidity (40%, n=299) showed twice the fatality (CFR 14%) of the others (CFR 7%; P=0.001). Hypertension (Htn) was the second-commonest comorbidity (29.5%, n=221), with similar CFR to diabetes (15% and 7% for Htn and non-Htn, respectively), but with higher significance (P=0.0006167). Although only 4% (n=30) heart failure (HF) was reported, the CFR (40%) was much higher than in those without it (8%). A similar rate (4%) for chronic kidney disease was reported, with CFRs of 33% and 9% among those with and without it, respectively (P=0.00048). Ischemic heart disease was 11% (n=74), followed by chronic liver disease (0.4%) and history of smoking (1%); however, these were not significant due to the sample sizes. Treatment indicated standard care and Hcq alone or in combination were superior (CFR of 4% and 0.5%, respectively) compared to favipiravir (25%) or Dex (38.5%) independently or in combination (35.4%). Furthermore, Hcq performed well (CFR 9%) when combined with Dex (9%; P=4.28–(26)). CONCLUSION: The dominance of diabetes and other comorbidities with significant association with CFR implied existence of a common virulence mechanism. The superiority of low-dose Hcq and standard care over antivirals warrants further studies.
format Online
Article
Text
id pubmed-10162097
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-101620972023-05-06 Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals Said, Kamaleldin B Alsolami, Ahmed Alreshidi, Fayez Saud Fathuddin, Anas Alshammari, Fawwaz Alrashid, Fauwaz Aljadani, Ahmed Aboras, Rana Alreshidi, Fatmah Alghozwi, Mohammed H Alshammari, Suliman F Alharbi, Nawaf F J Multidiscip Healthc Original Research INTRODUCTION: The lack of feasible therapies and comorbidities aggravate the COVID-19 case–fatality rate (CFR). However, reports examining CFR associations with diabetes, concomitant cardiovascular diseases, chronic kidney disease, and chronic liver disease (CLD) are limited. More studies assessing hydroxychloroquine (Hcq) and antivirals are needed. PURPOSE: To examine associations of COVID-19 CFR in comorbid patient groups each with single comorbidities and after treatment with Hcq, favipiravir, and dexamethasone (Dex), either alone or in combination versus standard care. METHODS: Using statistical analysis, we descriptively determined these associations among 750 COVID-19 patient groups during the last quarter of 2021. RESULTS: A diabetes comorbidity (40%, n=299) showed twice the fatality (CFR 14%) of the others (CFR 7%; P=0.001). Hypertension (Htn) was the second-commonest comorbidity (29.5%, n=221), with similar CFR to diabetes (15% and 7% for Htn and non-Htn, respectively), but with higher significance (P=0.0006167). Although only 4% (n=30) heart failure (HF) was reported, the CFR (40%) was much higher than in those without it (8%). A similar rate (4%) for chronic kidney disease was reported, with CFRs of 33% and 9% among those with and without it, respectively (P=0.00048). Ischemic heart disease was 11% (n=74), followed by chronic liver disease (0.4%) and history of smoking (1%); however, these were not significant due to the sample sizes. Treatment indicated standard care and Hcq alone or in combination were superior (CFR of 4% and 0.5%, respectively) compared to favipiravir (25%) or Dex (38.5%) independently or in combination (35.4%). Furthermore, Hcq performed well (CFR 9%) when combined with Dex (9%; P=4.28–(26)). CONCLUSION: The dominance of diabetes and other comorbidities with significant association with CFR implied existence of a common virulence mechanism. The superiority of low-dose Hcq and standard care over antivirals warrants further studies. Dove 2023-05-01 /pmc/articles/PMC10162097/ /pubmed/37153358 http://dx.doi.org/10.2147/JMDH.S403700 Text en © 2023 Said et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Said, Kamaleldin B
Alsolami, Ahmed
Alreshidi, Fayez Saud
Fathuddin, Anas
Alshammari, Fawwaz
Alrashid, Fauwaz
Aljadani, Ahmed
Aboras, Rana
Alreshidi, Fatmah
Alghozwi, Mohammed H
Alshammari, Suliman F
Alharbi, Nawaf F
Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals
title Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals
title_full Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals
title_fullStr Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals
title_full_unstemmed Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals
title_short Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals
title_sort profiles of independent-comorbidity groups in senior covid-19 patients reveal low fatality associated with standard care and low-dose hydroxychloroquine over antivirals
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162097/
https://www.ncbi.nlm.nih.gov/pubmed/37153358
http://dx.doi.org/10.2147/JMDH.S403700
work_keys_str_mv AT saidkamaleldinb profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals
AT alsolamiahmed profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals
AT alreshidifayezsaud profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals
AT fathuddinanas profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals
AT alshammarifawwaz profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals
AT alrashidfauwaz profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals
AT aljadaniahmed profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals
AT aborasrana profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals
AT alreshidifatmah profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals
AT alghozwimohammedh profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals
AT alshammarisulimanf profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals
AT alharbinawaff profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals
AT profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals